Subscribe to Newsletter
Discovery & Development Formulation

The Sulforaphane Promise

| Helen Kuhlman | 4 min read

Sulforaphane has therapeutic potential in numerous areas but formulation is key. Can enteric coatings help find the way forward?

Discovery & Development Drug Discovery

New Antibiotic on the Block

| Jamie Irvine | 2 min read

New antibiotic candidate Clovibactin eliminates bacteria without developing resistance

Business & Regulation Profession

Hello – From Women in Pharma

| Miriam Kenrick, Sarah Sowerby | 10 min read

The Women in Pharma network aims to inspire, empower and shape the pharma industry to better serve women. Meet the minds behind the mission.

Discovery & Development Drug Discovery

The Chance to Stop – or Even Prevent – Neurodegenerative Diseases

| Andrea Pfeifer | 7 min read

Will our generation be the last to face untreatable Alzheimer’s disease? With predictive biomarkers and active immunotherapies, just maybe.

Business & Regulation Profession

Top Tips for Leadership

| Angela Osborne | 5 min read

The importance of experience, learning, collaboration, and dealing with environments dominated by men

Manufacture Contract Manufacturing Services

May the Outsource Be With You

| Nandu Deorkar, Greg Swan | 7 min read

Experts suggest that outsourcing CGT manufacturing capabilities to CDMOs brings additional benefits, although not without challenges

Manufacture Facilities

Cell Culture Media Is Big Business

| 4 min read

Merck’s Darren Verlenden discusses the strategy and ethics behind the expansion plan in Lenexa, Kansas

Manufacture Advanced Medicine

The Sickle Cell Solution

| Jamie Irvine

Editas and Azzur Group scale up their efforts against sickle cell disease with experimental gene editing medicine EDIT-301

Discovery & Development Drug Delivery

The VLP Promise

| Nicholas (Nik) Barbet | 4 min read

Here’s why virus-like particles could open a new chapter in combating disease.

Discovery & Development Drug Delivery

The Cutting Room Floor

| Jamie Irvine | 2 min read

Scientists are targeting EV-A71 RNA viruses using an adeno-associated virus-delivered CRISPR-Cas13 editor

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register